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(1960–2004) search and discussed the available literature on
acute pancreatitis (limited to human pancreatitis). The Work-
ing Group held many general discussions in order to reach a
consensus on the content of the Guidelines. After producing a
draft, the Publishing Committee of the JPN Guidelines for the
Management of Acute Pancreatitis posted it on a website and
asked for comments and criticisms. Subsequently, a ﬁnal ver-
sion of the Guidelines was published in Japanese in 2003. The
Publishing Committee is now making the Guidelines available
to a much wider readership by bringing out an English
version.
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Introduction
Acute pancreatitis is often managed clinically, not only
by specialists in surgery, internal medicine, and emer-
gency medicine but also by general physicians, gastro-
enterologists, and general surgeons. Consequently, the
Guidelines have been prepared in order to help these
physicians to diagnose acute pancreatitis accurately and
to manage patients by means of an appropriate treat-
ment policy, thus improving survival rates. According to
the available literature, the mortality rate for patients
with severe acute pancreatitis ranged between 30% and
21.4% from 1987 to 1999. Which cases are likely to be
fatal? Which categories of morbidity are likely to
become more severe? And under what circumstances
should patients be transferred to a special hospital?
There is a great need for Guidelines that clearly answer
these and other questions.
Abstract
The JPN Guidelines for the Management of Acute
Pancreatitis are organized under the subject headings: epide-
miology, diagnosis, management strategy, severity assessment
and transfer criteria, management of gallstone pancreatitis,
nonsurgical management, and surgical management. The
Guidelines contain cutting-edge information on each of these
subjects, as well as a section on the Japanese medical insur-
ance system which provides information that should prove
useful to physicians in other countries. The quality of the
evidence was evaluated by the evidence-based classiﬁcation
method used at the Cochrane Library. The levels of recom-
mendation of the individual management methods contained
in the Guidelines were determined on the basis of the evalua-
tion of evidence by the consensus of the members of the
Working Group (see below). The Japanese Society for Ab-
dominal Emergency Medicine, the Japan Pancreas Society,
and the Research Group for Intractable Diseases and Refrac-
tory Pancreatic Diseases (which is sponsored by the Japanese
Ministry of Health, Labour, and Welfare) were commissioned
to produce the JPN Guidelines for the Management of Acute
Pancreatitis. A Working Group of 20 physicians specializing
in pancreatic diseases and emergency medicine investigated
and analyzed 14821 cases retrieved by means of a Medline
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Several sets of evidence-based guidelines for the
management of acute pancreatitis have been published;
those of the Atlanta Symposium of 1992,1 the United
Kingdom Guidelines of 1998,2 and the Santorini Con-
sensus Conference of 19993 are representative. How-
ever, they were based on the evidence available at the
time, and the validity of any set of guidelines is short-
lived and guidelines need to be revised every 2 years.1
Indeed, new evidence is reported almost daily, and
guidelines for management in clinical settings are
changing nearly as fast, thanks to the remarkable ad-
vances in medical equipment and treatment techniques
developed in recent years. The International Associa-
tion of Pancreatology guidelines4  were most recently
published in 2002, but they are concerned solely with
the surgical management of acute pancreatitis.
The Guidelines Publishing Committee very much
hopes that this publication will help clinicians world-
wide to become familiar with the Guidelines, and the
Committee hopes that those professionals will offer
their comments and criticisms once they have had the
opportunity to compare them with the guidelines in use
in their own countries.
Purpose of the Guidelines
The mortality rate among patients with severe acute
pancreatitis remains high, although various current di-
agnostic criteria, methods of severity assessment, and
new treatments have been used at a number of institu-
tions. However, there are inter-institutional differences
in the ways in which the disease is managed, due to the
lack of evidence-based guidelines.
In view of this situation, the Guidelines have been
formulated with the aim of providing practical manage-
ment guidelines to clinicians engaged in the manage-
ment of acute pancreatitis. The Working Group has
striven to ensure that the Guidelines will help general
clinicians not only to assess the severity of acute pancre-
atitis promptly but also to manage the disease appropri-
ately and efﬁciently. The Guidelines should also help
patients, their families, and the general public to acquire
better knowledge of acute pancreatitis, and thereby
lead to a better standard of medical management based
on mutual understanding between those who provide
medical treatment and those who receive it.
How the Guidelines were formulated
With evidence-based medicine (EBM) as the core con-
cept, an initial draft of the Guidelines was prepared by
members of the Guidelines Preparation Committee and
the Working Group, both of which consisted of special-
ists from the Japanese Society of Abdominal Emer-
gency Medicine, who searched the available documents
and evaluated the evidence they found there5. Follow-
ing this process, a Guidelines Investigation Committee
— consisting of members of the Working Group, the
Japan Pancreas Society, and the Research Group for
Intractable Diseases and Refractory Pancreatic Dis-
eases — was formed to examine the draft Guidelines.
In addition to the Investigation Committee, an Evalu-
ation Committee — whose members were drawn from
the Japanese Society of Abdominal Emergency Medi-
cine, the Japanese Ministry of Health, Labour, and
Welfare, and several external institutions — was formed
to critique the Guidelines whenever necessary.
Deﬁning and extending the search of the literature
Works were selected as follows. Using “pancreatitis” as
the key search word, a MeSH-based exploration of the
Ovid Medline database (1960–2004) yielded approxi-
mately 28000 items under the headings “pancreatitis”,
“acute necrotizing pancreatitis,” and “alcoholic pancre-
atitis.” The items were then screened to conﬁne the
entries to those related to human pancreatitis. This
yielded 14821 items in English, and after examination of
all the titles and abstracts, 1348 were selected, and a
careful examination of the full texts was conducted.
Other sources quoted in these selected works, together
with works suggested by the specialist members, as well
as reports prepared by the Research Group, were in-
cluded in the examination.
Categories of evidence and the grading of
recommendations
The evidence obtained from each reference item was
evaluated in accordance with the scientiﬁc classiﬁcation
method used at the Cochrane Library (Table 1),6 and
the quality of evidence for each parameter associated
with the diagnosis and treatment of acute pancreatitis
was determined. The relevant terms used are explained
the footnote of Table 1.6 Based on the results obtained
from these procedures, recommendation grades of A to
E, were determined according to the deﬁnitions shown
in Table 2, and these recommendation grades are men-
tioned, as required, in the text of the Guidelines. The
grading is based on the Kish7 method of classiﬁcation.
Recommendations graded as either A or B indicate
high quality. However, those graded as D or E are
considered to be unacceptable. It must be borne in mind
that such recommendation grades merely represent
standards and should not be used to compel adherence
to a given method of medical management in an actual
clinical setting. The medical management method that
is applied should be selected after taking into account4 T. Takada et al.: Cutting-edge guidelines for management of acute pancreatitis
Table 1.
Categories of evidence (see footnote for explanation of terms).
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The evidence-based classiﬁcation used at the Cochrane Library: Oxford Centre for Evidence-
based Medicine, Levels of Evidence (May 2001) (http://www.cebm.net/levels_of_evidence.asp#levels)
5
 was used as a basis to evaluate evidence presented in each item of
literature, and the quality of evidence for each parameter associated with the diagnosis and treatment of acute pancreatitis wa
s determined
Differential
Therapy/prevention,
diagnosis/symptom
Economic
Level
etiology/harm
Prognosis
Diagnosis
prevalence study
and decision analyses
1a
SR (with homogeneity*)
SR (with homogeneity*) of
SR (with homogeneity*) of
SR (with homogeneity*) of
SR (with homogeneity*)
of RCTs
inception cohort studies;
Level 1 diagnostic studies;
prospective cohort studies
of  Level 1 economic
CDR
†
 
validated in different
CDR
†
 
with 1b studies from
studies
populations
different clinical centers
1b
Individual RCT (with
Individual inception
Validating** cohort study
Prospective cohort study
Analysis based on clinically
narrow conﬁdence
cohort study with 
>
80%
with good
†††
 
reference
with good follow-up****
sensible costs or alternatives;
Interval
‡
)
follow-up;  CDR
†
 
validated
standards; or CDR
†
 
tested
systematic review(s) of the
in a single population
within one clinical center
evidence; and  including
multiway sensitivity
analyses
1c
All or none
§
All or none case series
Absolute SpPins and
All or none case series
Absolute better-value or
SnNouts
††
worse-value analyses
††††
2a
SR (with homogeneity*)
SR (with homogeneity*) of
SR (with homogeneity*) of
SR (with homogeneity*) of
SR (with homogeneity*) of
of cohort studies
either retrospective cohort
Level 
>
2 diagnostic studies
2b and better studies
Level 
>
2 economic studies
studies or untreated control
groups in RCTs
2b
Individual cohort study
Retrospective cohort study or
Exploratory** cohort study
Retrospective cohort study,
Analysis based on clinically
(including low-quality
follow-up of untreated control
with good
†††  
reference
or poor follow-up
sensible costs or alternatives;
RCT; e.g., 
<
80%
patients in an RCT; derivation
standards; CDR
†
 
after
limited review(s) of the
follow-up)
of CDR
†
 
or validated on
derivation, or validated
evidence, or single studies;
split-sample
§§§
 
only
only  on split-sample
§§§
 
or
and including multiway
databases
sensitivity  analyses
2c
“Outcomes” research;
“Outcomes” research
Ecological studies
Audit or outcomes research
ecological studies
3a
SR (with homogeneity*)
SR (with homogeneity*) of
SR (with homogeneity*) of 3b
SR (with homogeneity*) of
of case-control studies
3b and better studies
and better studies
3b and better studies
3b
Individual case-control
Nonconsecutive study; or
Nonconsecutive
Analysis based on limited
study
without consistently applied
cohort study, or very limited
alternatives or costs, poor
reference standards
population
quality estimates of data,
but including sensitivity
analyses  incorporating
clinically sensible
variationsT. Takada et al.: Cutting-edge guidelines for management of acute pancreatitis 5
4
Case series (and poor-
Case series (and poor-quality
Case control study, poor or
Case series or superseded
Analysis with no sensitivity
quality cohort and
prognostic cohort studies***)
nonindependent reference
reference standards
analysis
case-control studies
§§
)
standard
5
Expert opinion without
Expert opinion without explicit
Expert opinion without
Expert opinion without
Expert opinion without
explicit critical appraisal, or
critical appraisal, or based on
explicit critical appraisal, or
explicit critical appraisal, or
explicit critical appraisal,
based on physiology, bench
physiology, bench research, or
based on physiology, bench
based on physiology, bench
or based on  economic
research, or “ﬁrst principles”
“ﬁrst principles”
research, or “ﬁrst principles”
research, or “ﬁrst principles”
theory or “ﬁrst principles”
Users can add a minus sign to denote the level that fails to provide a conclusive answer because of:
NOTE 1
EITHER a single result with a wide conﬁdence interval (such that, for example, an ARR in an RCT is not statistically sign
iﬁcant but whose conﬁdence intervals fail to exclude
clinically important beneﬁt or harm)
NOTE 2
OR a systematic review with troublesome (and statistically signiﬁcant) heterogeneity
NOTE 3
Such evidence is inconclusive, and therefore can only generate Grade D recommendations
SR, Systematic review; RCT, randomized controlled trial; ARR, absolute risk ratio
*
By “homogeneity,” the Publishing Committee means a systematic review that is free of worrisome variations (heterogeneity) in t
he directions and degrees of results between individual
studies. Not all systematic reviews with statistically signiﬁcant heterogeneity need be worrisome, and not all worrisome hetero
geneity need be statistically signiﬁcant. As noted above, studies
displaying worrisome heterogeneity should be tagged with a minus sign at the end of their designated level
†
Clinical decision rule (these are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category)
‡
See NOTE 2 for advice on how to understand, rate, and use trials or other studies with wide conﬁdence intervals
§
Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx
 
became available, but none now die on it
§§
By “poor-quality cohort study,” the Publishing Committee means one that failed to clearly deﬁne comparison groups and/or failed
 
to measure exposures and outcomes in the same
(preferably blinded) objective way in both exposed and nonexposed individuals, and/or failed to identify or appropriately contr
ol known confounders, and/or failed to carry out a sufﬁciently
long and complete follow-up of patients. By “poor-quality case-control study,” the Publishing Committee means one that failed t
o clearly deﬁne comparison groups and/or failed to measure
exposures and outcomes in the same (preferably blinded) objective way in both cases and controls, and/or failed to identify or 
appropriately control known confounders
§§§
Split-sample validation is achieved by collecting all the information in a single tranche, then artiﬁcially dividing this into 
“derivation” and “validation” samples
††
An “absolute SpPin” is a diagnostic ﬁnding whose speciﬁcity is so high that a positive result rules in the diagnosis. An “absol
ute SnNout” is a diagnostic ﬁnding whose sensitivity is so high
that a negative result rules out the diagnosis
†††
“Good reference standards” are independent of the test, and are applied blindly or objectively to all patients. “Poor reference
 
standards” are haphazardly applied, but are still independent
of the test. Use of a nonindependent reference standard (where the “test” is included in the “reference,” or where the “testing
” affects the “reference”) implies a Level 4 study
††††
“Better-value treatments” are clearly as good but cheaper, or better at the same or reduced cost. “Worse-value treatments” are 
as good and more expensive or worse and equally or more
expensive
**
“Validating studies” test the quality of a speciﬁc diagnostic test, based on prior evidence. An “exploratory study” collects 
information and trawls the data (e.g., using a regression analysis)
to ﬁnd which factors are “signiﬁcant”
***
By “poor-quality prognostic cohort study,” the Publishing Committee means a study in which sampling was biased in favor of p
atients who already had the target outcome, or the
measurement of outcomes was accomplished in fewer than 80% of study patients, or outcomes were determined in an unblinded, nono
bjective way, or there was no correction for confounding
factors
****
Good follow-up in a differential diagnosis study is more than 80%, with adequate time for alternative diagnoses to emerge (
e.g., 1–6 months, acute; 1–5 years, chronic)
“Good,” “better,” “bad,” and “worse” refer to the comparisons between treatments in terms of their clinical risks and beneﬁts6 T. Takada et al.: Cutting-edge guidelines for management of acute pancreatitis
the conditions prevailing in the relevant institution
(staff, experience, equipment, etc.) and the characteris-
tics of the individual patient.
Notes on the use of the Guidelines
The Guidelines are evidence-based and determined
with a grade for each medical practice, taking actual
conditions into account. The Guidelines specify the cri-
teria for the diagnosis of acute pancreatitis and the as-
sessment of its severity that have been prepared by the
Research Group and are in widespread use in Japan.
Because the Guidelines address so many different top-
ics, an index of all works used is included at the end of
the series of articles for the convenience of readers. The
dosages described in the text of the Guidelines are for
adult patients.
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